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Diagnostic Value of Molecular Confirmation Assays for Neisseria gonorrhoeae
The COBAS Amplicor system (Roche Diagnostics, Rot-
kreuz, Switzerland) is a widely used screening test for infec-
tions with Neisseria gonorrhoeae due to its excellent sensitivity
and ease of use. However, it has been found to cross-react with
certain commensal Neisseria species (1, 3, 4). Therefore, an
independent confirmation assay is mandatory.
In the May 2007 issue of the Journal of Clinical Microbiology,
Mangold et al. (2) presented a new confirmation assay which is
capable of distinguishing between N. gonorrhoeae and Neisseria
spp. in comparison to confirmation assays targeting the porA
pseudogene and the cppB gene. They obtained positive results
in their in-house assay for 102/181 (56%) COBAS Amplicor-
positive samples; the porA confirmation assay was positive for
69/181 (38%) samples, and the cppB assay detected 115/181
(64%) positive samples. Additionally, Mangold et al. reported
15%, 2%, and 4% positive results for COBAS Amplicor-neg-
ative samples with the cppB, porA, and in-house assays, respec-
tively. The presented data are discrepant from observations at
our institution. Upon optimization of published detection pro-
tocols, we have compared the performances of three assays
targeting the porA pseudogene (5), the cppB gene (6), and the
16S rRNA gene (in-house) for quality assurance. In samples
positive for all three targets, the cppB confirmation assay was
the most sensitive (mean crossing point [Cp], 25.9), followed by
the porA assay (mean Cp, 26.2) and the 16S rRNA gene assay
(mean Cp, 32.8).
Over a period of 6 months, 398 samples yielded a positive
COBAS Amplicor result (optical density [OD] of 0.2, as
recommended by the manufacturer). Of these 398 samples,
258 samples (64.8%) were negative in all three confirmation
assays. The remaining 140 samples (35.2%) yielded a positive
result in at least two of the confirmation assays, with the ma-
jority being positive in all three assays (128/140 [91.4%]). Eight
of 140 samples (5.7%) were negative in the 16S rRNA gene
assay, probably due to small DNA amounts in the sample, as
this assay is less sensitive than the other two confirmation
assays, which is corroborated by the fact that 2/8 samples
showed an OD value lower than 2.0 when initially tested in the
COBAS Amplicor system. Four specimens were positive in the
16S rRNA gene and porA detection assays only and were
interpreted as gonococci lacking the cppB-harboring plasmid
(2.9%); the COBAS Amplicor value was above 2.0 OD in all
four samples. Taken together for 136/140 (97.1%) specimens,
the porA and cppB confirmation assays were concordantly pos-
itive.
In contrast to the findings of Mangold et al., we did not
obtain positive results for the confirmation assays when ap-
plied to COBAS Amplicor-negative samples.
The conflicting results might in part be explained by an
epidemiological distinct pool of N. gonorrhoeae isolates exam-
ined and an unfortunate study design, as modified interpreta-
tion guidelines for the COBAS Amplicor assay were used by
Mangold et al. Samples were considered positive if two out of
three runs gave a positive signal above an OD of 2.0, as op-
posed to one sample above an OD of 0.2 being sufficient. This
decreases the number of positive samples and inevitably has a
negative impact on the sensitivity of the screening assay. Pre-
sumably, this protocol accounts for the “false”-positive results
of the cppB plasmid assay (33/227). It would be interesting if
these samples were initially positive in the COBAS Amplicor
system (OD of 0.2) by use of the manufacturer’s interpreta-
tion criteria. Our analysis further cannot confirm the low sen-
sitivity of the porA detection assay, as the majority of our
specimens yielded positive results in all confirmation assays.
Regarding the in-house NsppID assay published by Mangold
et al., the design of the test itself is not completely conclusive:
N. gonorrhoeae displays 100% homology with strains of Neis-
seria polysaccharea at the binding site of the detection probe
(referred to as Npolysaccharea1 in the publication). N. polysac-
charea was not tested for cross-reactivity in the NsppID assay.
By use of an NCBI BLAST search, strains of Neisseria menin-
gitidis also display 100% homology in this region of the 16S
rRNA gene. Additionally, coamplification in PCRs should be
avoided if no important information is obtained by the coam-
plified product, as it is likely to decrease sensitivity. A confir-
mation assay for N. gonorrhoeae that coamplifies apathogenic
Neisseria spp. does not provide any additional information of
clinical relevance.
The studies indicate that the use of molecular diagnostic
assays for the detection of N. gonorrhoeae infection remains
challenging and that the characterization of the prevalence of
target genes in distinct epidemiological pools is important to
ensure accurate diagnosis.
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Authors’ Reply
We appreciate the comments forwarded by Dr. Peter-Get-
zlaff and colleagues regarding our recent publication of a
confirmatory assay for Neisseria gonorrhoeae. All are in
agreement that confirmation of positive results from the
Roche COBAS N. gonorrhoeae assay (Roche Diagnostics,
Indianapolis, IN) is necessary; however, several important
points must be made.
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First, there are significant differences in the interpretive
guidelines specified for the COBAS Amplicor CT/NG assay
between the United States and Europe. The European guide-
lines indicate that a single 0.2 A450 result is a presumptive
positive for N. gonorrhoeae, with a recommendation for retest-
ing for confirmation. However, in the U.S. product insert,
recommendations define an equivocal zone and call for re-
peated testing of specimens reading between 0.2 and 3.5 A450;
at least two of three results (of the initial and the duplicate
repeats) must measure 2.0 A450 in order to call the sample
presumptively positive for N. gonorrhoeae. These were the
guidelines used, appropriately, in our study (3). The U.S. rec-
ommendations were at least partially based on a study by Van
Der Pol et al. (5), which showed that employing the equivocal
zone retesting algorithm increased specificity to 98.6 to 99.9%,
with little effect (0.1 to 4.9% decrease) on sensitivity in most
specimen types. Our own data support this conclusion, as in-
dicated by Table 1.
As indicated, a significant number of specimens that resulted
in an initial A450 value of 0.2 or greater do not repeat with a
value of 2.0 or greater. The percentage of specimens that are
positive with repeat testing increases with the initial A450 value,
with 94% of specimens with an initial value of 3.5 or greater
remaining presumptive positive upon repeat testing; 64% of
these will ultimately be positive for N. gonorrhoeae, as indi-
cated by our 16S-based speciation assay (NsppID).
Although the equivocal zone retesting algorithm improves
the specificity of the COBAS N. gonorrhoeae assay, significant
numbers of false-positive results are still generated during test-
ing of low-prevalence populations, leading to the recommen-
dation by the Centers for Disease Control and Prevention that
presumptive N. gonorrhoeae infection should be confirmed us-
ing independent testing for a different N. gonorrhoeae-specific
target (2). We developed the NsppID assay to function as this
confirmatory test. Once again, our results (as listed in Table 1)
identifying nongonorrheal Neisseria spp. in the presumptive
positive specimens after repeat testing reinforce the value of a
second independent test.
In their letter, Peter-Getzlaff and colleagues indicated that
the 16S assay used in their studies was less sensitive than either
the cppB or the porA assay. Most published 16S assays (and
possibly theirs as well) for the confirmation of N. gonorrhoeae
were designed to amplify only N. gonorrhoeae, whereas our
assay was designed to amplify many different Neisseria spp.,
with mismatches under the probe differentiating the various
species. As described in our paper, the sensitivity of our assay
was four genome copies of N. gonorrhoeae per reaction, even in
the presence of 40-fold excess concentrations of the nongon-
orrheal Neisseria spp. Indeed, due to the melt curve analysis
that differentiates between the Neisseria spp., we were able to
detect dual infections in six clinical specimens. In comparison,
the optimized porA assay had an analytical sensitivity of 20
genome copies of N. gonorrhoeae per reaction. In addition,
although the optimized cppB assay detected more of the
COBAS-positive samples than NsppID, we question the spec-
ificity of this assay, as a significant number of the discrepant
specimens did amplify a nongonorrheal Neisseria sp. in the
absence of any indication of N. gonorrhoeae in our NsppID
assay. Several other laboratories have also found the cppB
assay to be less specific than first thought (1, 4).
At the beginning of this project, there was only a single
GenBank entry of a nongonorrheal Neisseria strain (one of
several N. polysaccharea strains entered) that was identical in
sequence to N. gonorrhoeae in the fluorescein-labeled probe
region, and the assay was designed based on that information.
Since that time, additional sequences have been entered into
the GenBank database, and the list of entries with the 30-base
sequence identical to that of N. gonorrhoeae in the fluorescein-
labeled probe region includes some, but not all, strains of two
additional Neisseria spp. (N. meningitidis and N. lactamica). Of
these three nongonorrheal Neisseria spp., only N. lactamica has
been shown to produce a false-positive result in the COBAS
Amplicor CT/NG assay. Neither N. meningitidis nor N. polysac-
charea has been shown to cross-react in a similar fashion. In
our analytical validation, we tested a single strain of N. lac-
tamica (ATCC 23970); the melting temperature peak observed
in the melt curve analysis was over 6°C lower than that ob-
served for all of the N. gonorrhoeae strains tested and was lower
than that for any of the other Neisseria specimens tested
as well. For these reasons, after analytical validation of the
NsppID assay, we continued with the validation by using clin-
ical specimens (endocervical swabs, urogenital swabs, or male
urine). A specimen that was presumptive N. gonorrhoeae pos-
itive after repeat testing using the COBAS Amplicor CT/NG
assay and that amplified in the NsppID assay with a resultant
melting temperature of approximately 58°C was called N. gon-
orrhoeae positive. As pointed out by Peter-Getzlaff and col-
leagues, there remains the small possibility that N. polysac-
charea, N. meningitidis, or N. lactamica could give the same
NsppID result, but the likelihood of this occurring is very small
if used as a confirmatory test of the COBAS Amplicor CT/NG
assay with the more restrictive U.S. guidelines on the type of
specimens described.
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